Report Date: Thursday, July 23, 2026, before market open | Call at 8:00 a.m. ET
WST has been one of the strongest performers in med-tech/life-science tools over the past year, roughly tripling in relative strength terms — the stock has run from ~$220 in July 2025 to ~$358 as of July 22, 2026, a gain of over 60%. Much of that re-rating has come in two violent post-earnings gaps: a jump from ~$210 to ~$279 after the July 2025 print, and another leg from ~$274 to ~$310 after the Q1 2026 beat-and-raise on April 23, 2026. The stock has since continued grinding higher into this print, touching an all-time high near $367 in early July.
That run has pushed valuation well above historical norms — market cap of roughly $25.4 billion, a P/E near 48x and PEG around 3x. Notably, shares are now trading above the Street's average price target (~$350–$361), meaning the bar for another "beat-and-raise" is high and the market has already priced in continued upside surprises.
Sentiment/positioning: Consensus is overwhelmingly bullish — of 16 covering analysts, 14 rate the stock Strong Buy, one Moderate Buy, and one Hold, with a Street-high target of $400. KeyCorp recently raised its price target to $390 (from $350) with an Overweight rating, and TD Cowen reiterated its Buy rating ahead of the print.
Q1 was a blowout: net sales of $844.9 million grew 21% reported / 15.3% organic, adjusted EPS of $2.13 rose 47% y/y, and adjusted operating margin expanded 350bps to 21.4%. Management raised full-year 2026 guidance meaningfully — revenue to $3.295B–$3.350B and adjusted EPS to $8.40–$8.75 (from $7.85–$8.20), pushing organic growth guidance back up to the long-term algorithm of 7–9%. The upgrade was driven by a broad-based acceleration: HVP Components grew 23% organically, with both GLP-1 (contributing ~10% of total company sales, consistent with the prior quarter) and non-GLP-1 revenue (high-teens growth) contributing, alongside 26% growth in Biologics and a 66% y/y increase in Annex 1-related project volume. Management also flagged an operational-excellence initiative (faster hiring/training, multi-site qualification, cross-site knowledge transfer) as a key margin and capacity driver.
1. Can HVP Components momentum continue? This remains the single most important line item — 48% of sales and the primary earnings driver. Watch for confirmation that both GLP-1 (mid-to-high-teens growth guided for the year) and non-GLP-1 (low-double-digit growth guided) demand held up, and whether capacity-ramp initiatives in Europe (Eschweiler, Waterford) continued to translate into better-than-planned output.
2. Margin cadence. Management guided Q2 adjusted operating margin to be "roughly in line" with Q1's 21.4%, with a bigger step-up expected in the second half. Any commentary on commodity/oil cost inflation (management flagged a low-single-digit-million net headwind after mitigation from rising oil/logistics costs tied to Middle East tensions) and tariff mitigation will be important.
3. SmartDose/AbbVie divestiture timing. WST continues to expect a mid-2026 close of the SmartDose 3.5mL sale to AbbVie (the ~$110 million Tempe, AZ facility transaction announced in January). Confirmation of close timing matters because it affects the organic growth base (the business generated $55 million in H2 2025 revenue being excluded from organic comps) and second-half segment mix.
4. West Vantage / CGM roll-off. A previously flagged ~$40 million second-half headwind from the exit of a legacy CGM (continuous glucose monitoring) contract in West Vantage (formerly Contract-Manufactured Products) should start showing up; management called Q3 the likely trough for that segment, with new drug-handling business (~$20 million of revenue this year, higher-margin) ramping to backfill capacity.
5. Annex 1 / regulatory upgrade tailwind. Company has guided to a ~200bps annual revenue contribution from Annex 1-driven upgrades (standard-to-HVP conversions) for multiple years, with a total addressable pool of "at least 6 billion units" still to convert; watch for updates on U.S./Asia expansion of this trend beyond Europe.
6. CEO transition. This is likely one of outgoing CEO Eric Green's final quarterly calls — the company has since named Michel Lagarde as President & CEO effective August 31, 2026, with Green retiring the same day and Robert Friel stepping in as Board Chair. Investors should listen for continuity messaging and any early signals on strategic priorities under the incoming CEO.
7. Daikyo Seiko partnership renewal. On July 14, 2026, WST renewed its long-standing Crosslicense and Distributorship Agreements with Daikyo Seiko (in which WST holds a 49% stake) for another 10-year term on substantially similar terms to the prior 2017 agreement — reinforcing the Crystal Zenith/high-value component supply relationship, though this is largely a housekeeping continuation rather than a new catalyst.
A wildcard for the sector: reports this week indicate the Trump administration is planning steep, phased tariffs on generic drug manufacturers that don't move production to the U.S. by 2028, which some commentators warn could raise costs for lower-priced generic medicines. While this targets drug manufacturers rather than component suppliers directly, it's a reminder of the tariff/onshoring policy environment that WST management has repeatedly cited as both a cost headwind and (via Annex-1-style standardization/onshoring of manufacturing) a potential tailwind for HVP upgrade demand.
WST enters this print in a "prove it again" position: fundamentals have been outstanding (four consecutive large beats, HVP/GLP-1/Annex-1/Biologics all firing at once, margins expanding), and guidance was already raised meaningfully just one quarter ago. The risk is less about the business — which continues to show broad-based, multi-driver strength — and more about valuation and expectations: shares trade above average analyst price targets at ~48x earnings, so even a solid in-line quarter could see a muted or negative reaction if second-half guidance, margin cadence, or SmartDose/CGM transition details disappoint elevated expectations. Key swing factors for the stock reaction: (1) magnitude of any Q2 beat and whether full-year guidance is raised again, (2) second-half margin trajectory confirmation, and (3) any incremental color on the CEO transition and capital deployment (the company has a fresh $1 billion buyback authorization, having already repurchased ~$298 million in Q1).